Nationwide surveillance of antimicrobial susceptibility of 509 rapidly growing mycobacteria strains isolated from clinical specimens in Japan
Open Access
- 9 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 11 (1), 1-10
- https://doi.org/10.1038/s41598-021-91757-4
Abstract
This study aimed to identify effective treatments against rapidly growing mycobacteria (RGM) infections by investigating the minimum inhibitory concentrations (MIC) of 24 antimicrobial agents and their molecular mechanisms of resistance. In total, 509 clinical RGM isolates were identified by analyzing the sequences of three housekeeping genes (hsp65, rpoB, and sodA), and their susceptibilities to 24 antimicrobial agents were tested. We also performed sequencing analysis of antimicrobial resistance genes (rrl, rrs, gyrA, and gyrB). To identify Mycobacteroides abscessus group subspecies, we performed PCR-based typing and determined the sequevar of erm(41). We identified 15 RGM species, most of which were susceptible to amikacin and linezolid. Among these species, arbekacin and sitafloxacin had the lowest MIC among the same class of antimicrobials. The MIC of rifabutin for M. abscessus subsp. abscessus (MAB) was lower than that for M. abscessus subsp. massiliense (MMA). The proportion of MAB isolates with MIC ≤ 2 mg/L for rifabutin was significantly higher than that of MMA [MAB: 50/178 (28.1%) vs. MMA: 23/130 (17.7%); p = 0.041]. In summary, our study revealed the antimicrobial susceptibility profile of 15 RGM species isolated in Japan and indicated that arbekacin, sitafloxacin, and rifabutin may be possible therapeutic options for RGM infections.Funding Information
- Japan Society for the Promotion of Science (JP20K22755, JP19K08938)
This publication has 32 references indexed in Scilit:
- New Rapid Scheme for Distinguishing the Subspecies of the Mycobacterium abscessus Group and Identifying Mycobacterium massiliense Isolates with Inducible Clarithromycin ResistanceJournal of Clinical Microbiology, 2013
- Mycobacterium abscessus: a new antibiotic nightmareJournal of Antimicrobial Chemotherapy, 2012
- Genetic analysis of new 16S rRNA mutations conferring aminoglycoside resistance in Mycobacterium abscessusJournal of Antimicrobial Chemotherapy, 2011
- Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm (41) and rrl SequencingAntimicrobial Agents and Chemotherapy, 2011
- Mycobacterium massiliense is differentiated from Mycobacterium abscessus and Mycobacterium bolletii by erythromycin ribosome methyltransferase gene (erm) and clarithromycin susceptibility patternsMicrobiology and Immunology, 2010
- In vitro drug susceptibility of 2275 clinical non-tuberculous Mycobacterium isolates of 49 species in The NetherlandsInternational Journal of Antimicrobial Agents, 2010
- A Novel Gene,erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates ofMycobacterium abscessusbut Is Absent fromMycobacterium chelonaeAntimicrobial Agents and Chemotherapy, 2009
- Dissection of phylogenetic relationships among 19 rapidly growing Mycobacterium species by 16S rRNA, hsp65, sodA, recA and rpoB gene sequencingInternational Journal of Systematic and Evolutionary Microbiology, 2004
- rpoB -Based Identification of Nonpigmented and Late-Pigmenting Rapidly Growing MycobacteriaJournal of Clinical Microbiology, 2003
- Clinical and Laboratory Features of Mycobacterium mageritenseJournal of Clinical Microbiology, 2002